Abstract
We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients. The DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGAT) is important in glioblastoma resistance to alkylating antitumor agents. In vitro, cisplatin (CDDP) decreases MGMT activity in a time- and dose-dependent manner. Thirty-three recurrent malignant glioma patients (20 GBM-13 AA) were treated at recurrence or progression with a CDDP and TMZ association. On days 1 and 2, iv CDDP (40 mg/sqm) was administered. TMZ (at the dose of 200 mg/sqm) was administered as a single oral daily-dose on days 2–6 (starting 24 h after the first CDDP dose), the cycle was repeated every 4 weeks. All patients had been previously treated with surgery followed by radiotherapy and CDDP + BCNU chemotherapy. The primary endpoint of the study was progression free survival at 6 months (PFS-6). Secondary endpoints included radiological response and toxicities. Thirty-three patients received a total of 113 courses (median 3 range 1–11). Complete responses were not observed, partial responses were 18.8% with an additional 39.9% of stable disease. For the whole group of patients the PFS at 6 and 12 months was 52% and 15% with a median TTP of 33 weeks. PFS-6 for GBM and Anaplastic astrocytoma (AA) were 35% and 69%, respectively. PFS-12 for GBM and AA were 13.8% and 17.3%, respectively. Median TTP was 21.3 and 39.5 weeks, respectively. The principal toxic effects of the regimen were: neutropenia (5 WHO grade IV), thrombocytopenia (4 WHO grade IV), nausea and vomiting.
Similar content being viewed by others
References
Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol 3: 509-524, 2002
Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 25: 606-611, 2002
Trippoli S, Pelagotli F, Wessori A, Vacca F, Vaiani M, Maltoni S: Survival of patients with recurrent malignant glioma treated with Temozolomide: a retrospective observational study. Drugs RD 4: 285-291, 2003
Macdonald DR: Temozolomide for recurrent high-grade glioma. Semin Oncol 28: 3-12, 2001
Dinnes J, Cave C, Huang S, Milne R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86: 499-500, 2002
Spence AM, Berger MS, Livingston RB, Ali-Osman F, Griffin B: Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neuro-Oncol 2: 187-191, 1992
Ashby LS, Shapiro WR: Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neuro-Oncol 51: 67-86, 2001
Schuller E, Seidl R, Wandl C, Dieckmann K, Slavc I: Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. Pediatr Hematol Oncol 18: 253-258, 2001
Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L: Efficacy of ‘8-drugs-in-one-day’ combination in treatment of recurrent GBM patients. J Neuro-Oncol 12: 153-158, 1992
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
Kaplan EL, Meyer P: Non parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000
Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002
Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Ruzzolino P, Amista P, Pinna G, Scienza R, Ermani M: A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58: 1759-1664, 2002
Boiardi A, Silvani A, Ciusani E, Watson A, Margison G, Berger E, Lucas C, Giroux B: Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. J Neuro-Oncol 52: 149-156, 2001
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS: Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283, 2002
Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG: Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5: 1629-1637, 1999
D'Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP: Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671, 2000
Osoba D, Brada M, Yung WK, Prados M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18: 1481-1491, 2000
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000
Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001
Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman, M, Iuzzolino P, Turazzi S, Monfardini S: Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63: 38-41, 2002
Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4: 39-43, 2002
Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M: Temozolomide as second-line chemotherapy for relapsed gliomas. J Neuro-Oncol 57: 247-251, 2002
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20: 1383-1388, 2002
Schold Jr S, Kuhn J, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-Oncology 2: 34-39, 2000
Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M: Sequential administration of temozolomide and fotemustine: depletion of O6-alkylguanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10: 831-838, 1999
Stupp R, Gander M, Leyvarz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2: 552-560, 2001
Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP: Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6: 4110-4118, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silvani, A., Eoli, M., Salmaggi, A. et al. Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. J Neurooncol 66, 203–208 (2004). https://doi.org/10.1023/B:NEON.0000013479.64348.69
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000013479.64348.69